| Keyword search (4,164 papers available) | ![]() |
"Dasgupta K" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Associations of pregnancy complications with paternal cardiovascular risk: a retrospective cohort study | Mussa J; Wen L; Sharafi M; Gouin JP; Rahme E; Dasgupta K; | 41407531 PSYCHOLOGY |
| 2 | Methodological considerations for the measurement of arterial stiffness using applanation tonometry | Cooke AB; Kuate Defo A; Dasgupta K; Papaioannou TG; Lee J; Morin SN; Murphy J; Santosa S; Daskalopoulou SS; | 33031179 PERFORM |
| 3 | Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. | Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Laroc | 27118291 HKAP |
| 4 | Neighbourhood walkability and home neighbourhood-based physical activity: an observational study of adults with type 2 diabetes. | Hajna S, Kestens Y, Daskalopoulou SS, Joseph L, Thierry B, Sherman M, Trudeau L, Rabasa-Lhoret R, Meissner L, Bacon SL, Gauvin L, Ross NA, Dasgupta K, Diabetes, GPS, and Walkablilty Study Group | 27613233 HKAP |
| 5 | Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension. | Dasgupta K, Rosenberg E, Joseph L, Cooke AB, Trudeau L, Bacon SL, Chan D, Sherman M, Rabasa-Lhoret R, Daskalopoulou SS, SMARTER Trial Group | 28074635 HKAP |
| 6 | Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. | Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell | 28449828 HKAP |
| 7 | Stigma and Its Association With Glycemic Control and Hypoglycemia in Adolescents and Young Adults With Type 1 Diabetes: Cross-Sectional Study. | Brazeau AS, Nakhla M, Wright M, Henderson M, Panagiotopoulos C, Pacaud D, Kearns P, Rahme E, Da Costa D, Dasgupta K | 29678801 HKAP |
| 8 | Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. | Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, | 29731013 NA |
| Title: | Methodological considerations for the measurement of arterial stiffness using applanation tonometry | ||||
| Authors: | Cooke AB, Kuate Defo A, Dasgupta K, Papaioannou TG, Lee J, Morin SN, Murphy J, Santosa S, Daskalopoulou SS | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/33031179/ | ||||
| DOI: | 10.1097/HJH.0000000000002665 | ||||
| Publication: | Journal of hypertension | ||||
| Keywords: | |||||
| PMID: | 33031179 | Category: | Date Added: | 2020-10-08 | |
| Dept Affiliation: |
PERFORM
1 Division of Experimental Medicine, Department of Medicine, McGill University. 2 Cardiovascular Health Across the Lifespan (CHAL) Program, Research Institute of the McGill University Health Centre. 3 Division of Internal Medicine, Department of Medicine, McGill University Health Center. 4 Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada. 5 Biomedical Engineering Unit, First Department of Cardiology, Medical School, Hippokration Hospital, National and Kapodistrian University of Athens, Greece. 6 Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta. 7 Metabolism, Obesity and Nutrition Laboratory, PERFORM Centre. 8 Department of Health, Kinesiology, and Applied Physiology, Concordia University, Montreal, Quebec, Canada. |
||||
Description: |
Introduction: Accurate comparisons of carotid--femoral pulse wave velocity (cfPWV) within and across studies require standardized procedures. Guidelines suggest reporting the average of at least two cfPWV measurements; if the difference exceeds 0.5 m/s, a third measurement should be taken, and the median reported. Another method involves repeating measurements until two values are within 0.5 m/s. However, in many studies, duplicate measurements are averaged irrespective of the difference between readings. We evaluated the impact of these methods on the reported cfPWV value. Methods: Measurements of cfPWV (SphygmoCor) from five studies included individuals spanning a wide age range, with or without comorbid conditions, and pregnant women. In participants with at least three high-quality measurements, differences between the median value (MED) and the average of the first two cfPWV measurements (AVG1) and the average of two cfPWV measurements within 0.5 m/s (AVG2) were evaluated using paired t-tests and Bland--Altman plots. Results: Participants' mean age was 50 ± 14 years and BMI was 28.0 ± 5.5 kg/m (N = 306, 79% women). The overall mean difference was -0.10 m/s (95% CI 0.17 to -0.04) between MED and AVG1, and 0.11 m/s (95% CI 0.05--0.17) between MED and AVG2. The absolute difference exceeded 0.5 m/s in 34% (MED-AVG1) and 22% (MED-AVG2) of participants, and 1 m/s in 8% of participants (both MED-AVG1 and MED-AVG2). Scatter around the bias line increased with higher mean cfPWV values. Conclusion: Although the overall mean difference in cfPWV between protocols was not clinically relevant, large variation led to absolute differences exceeding 0.5 m/s in a large proportion of participants. |



